Biohaven Stock Down Fund's Turnaround Bet Sparks Hope
A patient biotech story gets a glimmer of hope as One Fund reveals a new $6 million stake in Biohaven. Here’s what th...
Controlling spending in your 20s comes down to consistent routines: track, limit impulse buys, and automate saving to reinforce discipline.
21,066 articlesA patient biotech story gets a glimmer of hope as One Fund reveals a new $6 million stake in Biohaven. Here’s what th...
BP plc shares slipped as leadership changes hit the headlines and energy markets swung on oil-price moves. This artic...
When SpaceX first hit the public markets, traders expected spectacle but not necessarily sustainability. A surprising...
As Agilent prepares to reveal its Q1 2026 results, investors want clarity on growth signals and margins. This guide b...
When a company director sells millions after a sharp rally, it stirs worry. But insider activity is nuanced. This gui...
As earnings season arrives, smart investors are drilling into Transcat's 2026 earnings outlook. This guide breaks dow...
A seismic shift in how the Fed communicates could redefine market expectations. This piece examines kevin warsh shift...
As 2025 earnings season unfolds, AvePoint faces a pivotal moment in cloud data governance and SaaS expansion. This gu...
A regulatory proposal released March 19 could ease capital buffers for many U.S. banks, freeing up funds for lending,...
AI infrastructure is fueling new demand for semiconductors. This guide explains how these semiconductor stocks could ...
MP Materials stands at the crossroads of national strategy and market demand for critical minerals. This guide outlin...
Sunrun’s stock tumbled on a day of mixed signals: strong quarterly revenue but cautious guidance for 2026. This artic...